1078627-36-7

Upstream product

• 1078627-30-1 (S)-2-amino-non-8-enoic acid hydrochloride 
• 352-34-1 4-fluoro-1-iodobenzene 
• 906063-12-5 (3R,5S)-5-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropylcarbamoyl)pyrrolidin-3-yl 4-fluoroisoindoline-2-carboxylate hydrochloride 
• 1078627-32-3 (S)-2-((4-fluoro-phenyl)amino)-non-8-enoic acid 

Downstream Products

• 1078623-96-7 (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-6-((4-fluoro-phenyl)-amino)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate 

Relevant academic research and scientific papers

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including